# US 2024/0191215 A1 · Materials and methods for improved phosphotransferases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0191215 A1
- Document ID: US20240191215A1
- Status: Published application
- Kind: A1
- Application number: 18/287,742
- Filed: 2022-04-20
- Published: 2024-06-13
- Earliest claimed: 2021-04-21
- Assignees: Janssen Biotech, Inc.
- Applicants: Janssen Biotech, Inc.
- Inventors: William Lloyd Perry, III
- Web page: https://patentgrep.com/patent/US20240191215A1

## CPC

- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- C12N 15/1034: {Isolating an individual clone by screening libraries}
- C12Q 1/48: involving transferase
- C12Y 207/01095: Kanamycin kinase (2.7.1.95), i.e. neomycin-kanamycin phosphotransferase
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES

## Abstract

Described herein are non-naturally occurring neomycin phosphotransferase (NPT) proteins and nucleic acid sequences encoding such NPT proteins. In a specific embodiment, the non-naturally occurring NPT proteins have reduced activity relative to wild-type NPT. The non-naturally occurring NPT proteins provided herein are useful as a selectable marker for screening transformed or transfected cells. Also provided herein are vectors and kits comprising a nucleic acid sequence encoding a non-naturally occurring NPT protein, and methods of producing cells expressing the non-naturally occurring NPT protein and a protein of interest or a non-coding RNA sequence of interest.

## Claims

### Claim 1

A non-naturally occurring neomycin phosphotransferase (NPT) with neomycin phosphotransferase activity, wherein the non-naturally occurring NPT comprises an amino acid sequence of a wild-type neomycin phosphotransferase with:
(a) amino acid substitutions at amino acid residues corresponding to amino acid residues 36 and 210 of SEQ ID NO:1, wherein the amino acid substitution at the amino acid residue corresponding to amino acid residue 36 of SEQ ID NO:1 is a substitution to methionine and the amino acid substitution at the amino acid residue corresponding to amino acid residue 210 of SEQ ID NO:1 is a substitution to alanine;
(b) amino acid substitutions at amino acid residues corresponding to amino acid residues 36 and 182 of SEQ ID NO:1, wherein the amino acid substitution at the amino acid residue corresponding to amino acid residue 36 of SEQ ID NO:1 is a substitution to methionine and the amino acid substitution at the amino acid residue corresponding to amino acid residue 182 of SEQ ID NO:1 is a substitution to aspartic acid;
(c) amino acid substitutions at amino acid residues corresponding to amino acid residues 36 and 218 of SEQ ID NO:1, wherein the amino acid substitution at the amino acid residue corresponding to amino acid residue 36 of SEQ ID NO:1 is a substitution to methionine and the amino acid substitution at the amino acid residue corresponding to amino acid residue 218 of SEQ ID NO:1 is a substitution to phenylalanine;
(d) amino acid substitutions at amino acid residues corresponding to amino acid residues 216 and 261 of SEQ ID NO:1, wherein the amino acid substitution at the amino acid residue corresponding to amino acid residue 216 of SEQ ID NO:1 is a substitution to glycine and the amino acid substitution at the amino acid residue corresponding to amino acid residue 261 of SEQ ID NO:1 is a substitution to asparagine;
(e) amino acid substitutions at amino acid residues corresponding to amino acid residues 36 and 218 of SEQ ID NO:1, wherein the amino acid substitution at the amino acid residue corresponding to amino acid residue 36 of SEQ ID NO:1 is a substitution to methionine and the amino acid substitution at the amino acid residue corresponding to amino acid residue 218 of SEQ ID NO:1 is a substitution to serine; or
(f) amino acid substitutions at amino acid residues corresponding to amino acid residues 36 and 216 of SEQ ID NO:1, wherein the amino acid substitution at the amino acid residue corresponding to amino acid residue 36 of SEQ ID NO:1 is a substitution to methionine and the amino acid substitution at the amino acid residue corresponding to amino acid residue 216 of SEQ ID NO:1 is a substitution to glycine.

### Claim 2

A non-naturally occurring neomycin phosphotransferase (NPT) with neomycin phosphotransferase activity, wherein the non-naturally occurring NPT comprises the amino acid sequence of SEQ ID NO:1 with:
(a) amino acid substitutions at positions 36 and 210 of SEQ ID NO:1, wherein the amino acid substitution at position 36 of SEQ ID NO:1 is a substitution to methionine and the amino acid substitution at position 210 of SEQ ID NO:1 is a substitution to alanine;
(b) amino acid substitutions at positions 36 and 182 of SEQ ID NO:1, wherein the amino acid substitution at position 36 of SEQ ID NO:1 is a substitution to methionine and the amino acid substitution at position 182 of SEQ ID NO:1 is a substitution to aspartic acid;
(c) amino acid substitutions at positions 36 and 218 of SEQ ID NO:1, wherein the amino acid substitution at position 36 of SEQ ID NO:1 is a substitution to methionine and the amino acid substitution at position 218 of SEQ ID NO:1 is a substitution to phenylalanine;
(d) amino acid substitutions at positions 216 and 261 of SEQ ID NO:1, wherein the amino acid substitution position 216 of SEQ ID NO:1 is a substitution to glycine and the amino acid substitution at position 261 of SEQ ID NO:1 is a substitution to asparagine;
(e) amino acid substitutions at positions 36 and 218 of SEQ ID NO:1, wherein the amino acid substitution at position 36 of SEQ ID NO:1 is a substitution to methionine and the amino acid substitution at position 218 of SEQ ID NO:1 is a substitution to serine; or
(f) amino acid substitutions at positions 36 and 216 of SEQ ID NO:1, wherein the amino acid substitution at position 36 of SEQ ID NO:1 is a substitution to methionine and the amino acid substitution at position 216 of SEQ ID NO:1 is a substitution to glycine.

### Claim 3 (depends on 1)

The NPT of claim 1, wherein the non-naturally occurring NPT has attenuated neomycin phosphotransferase activity as a selectable marker as compared to wild-type NPT.

### Claim 4 (depends on 1, 3)

The NPT of claim 1 or 3, wherein the wild-type NPT comprises an amino acid sequence that is at least 80%, at least 90%, or at least 98% identical to SEQ ID NO:1.

### Claim 5 (depends on 1, 3)

The NPT of claim 1 or 3, wherein the wild-type NPT comprises an amino acid sequence that is at least 60%, at least 65%, at least 70% or at least 75% identical to SEQ ID NO:1.

### Claim 6 (depends on 2)

The NPT of claim 2, wherein the non-naturally occurring NPT has attenuated neomycin phosphotransferase activity as a selectable marker as compared to wild-type NPT comprising the amino acid sequence of SEQ ID NO:1.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The NPT of any one of claims 1 to 6, wherein bacterial cells transfected or transformed with a nucleotide sequence encoding the non-naturally occurring NPT exhibit reduced colony formation as assessed by a colony formation assay after 48 hours of growth on plates containing 25 μg/mL, 75 μg/mL or 100 μg/mL kanamycin relative to bacterial cells transfected or transformed with a nucleotide sequence encoding wild-type NPT; and wherein optionally, the bacterial cells are E. coli.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The NPT of any one of claims 1 to 6, wherein mammalian cells transfected with an expression vector comprising a nucleotide sequence encoding the non-naturally occurring NPT exhibit reduced colony formation as assessed by a colony formation assay after 2 weeks of growth on tissue culture plates in media containing 500 μg/mL geneticin (G418) relative to mammalian cells transfected with the same expression vector but comprising a nucleotide sequence encoding wild-type NPT; and wherein optionally, the mammalian cells are HEK293 cells, CHO cells, PER.C6 cells, murine NS0 cells, fibrosarcoma HT-1080 cells, murine Sp2/0 cells, BHK cells, or murine C127 cells.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

The NPT of any one of claims 1 to 6, wherein G418 resistant colonies of mammalian cells transfected with an expression vector comprising a nucleotide sequence encoding the non-naturally occurring NPT are produced at frequencies ranging from 0.001% to 75% relative to G418 resistant colonies of mammalian cells transfected with the same expression vector but comprising a nucleotide sequence encoding wild-type NPT.

### Claim 10 (depends on 2)

The NPT of claim 2, wherein the non-naturally occurring NPT comprises the amino acid sequence of SEQ ID NO:38 (V36M, G210A), SEQ ID NO:39 (V36M, E182D), SEQ ID NO:40 (V36M, Y218F), SEQ ID NO:41 (D216G, D261N), SEQ ID NO:42 (V36M, Y218S), or SEQ ID NO:43 (V36M, D216G).

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A nucleic acid sequence comprising a first nucleotide sequence encoding the non-naturally occurring NPT of any one of claims 1 to 10.

### Claim 12 (depends on 11)

The nucleic acid sequence of claim 11, wherein the nucleic acid sequence further comprises a second nucleotide sequence encoding a second protein or a non-coding RNA; and wherein optionally, the second protein is a therapeutic protein.

### Claim 13 (depends on 11, 12)

The nucleic acid sequence of claim 11 or 12, wherein the first nucleotide sequence comprises the nucleotide sequence of SEQ ID NO:20, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO: 36, or SEQ ID NO:37.

### Claim 14 (depends on 11, 12, 13)

A vector comprising the nucleic acid sequence of any one of claims 11 to 13.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

An in vitro or ex vivo host cell comprising the non-naturally occurring NPT of any one of claims 1 to 10.

### Claim 16 (depends on 11, 12, 13, 14)

An in vitro or ex vivo host cell comprising the nucleic acid sequence of any one of claims 11 to 13, or the vector of claim 14.

### Claim 17 (depends on 16)

The cell of claim 16, wherein the nucleic acid sequence is stably integrated into the genome of the host cell.

### Claim 18 (depends on 15, 16, 17)

The cell of any one of claims 15 to 17, wherein the host cell further comprises a second nucleic acid sequence encoding a second protein or a non-coding RNA, and wherein the second protein is optionally a therapeutic protein; or wherein optionally, the second nucleic acid sequence encodes a non-coding RNA; and wherein optionally, the non-coding RNA is shRNA, miRNA, antisense RNA, guide RNA for Crispr nucleases, catalytic RNA, ribosomal RNA, or tRNA.

### Claim 19 (depends on 15, 16, 17, 18)

The cell of any one of claims 15 to 18, wherein the host cell is a bacterium, yeast cell, mammalian cell, plant cell; optionally wherein the mammalian cell is a human cell.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method for selecting cells with high copy numbers of a transgene and/or high expression levels of a transgene from a population of host cells in which the transgene was introduced, the method comprising:
(a) introducing into a population of host cells a nucleic acid sequence comprising:
(i) a first nucleotide sequence encoding the non-naturally occurring neomycin phosphotransferase (NPT) of any one of claims 1 to 10; and
(ii) a second nucleotide sequence comprising the transgene; and
(b) selecting cells that grow in the presence of a neomycin phosphotransferase substrate from the population of host cells in which the nucleic acid sequence was introduced.

### Claim 21 (depends on 20)

The method of claim 20, wherein:
(a) the selected cells comprise a 2 to 1000 times higher copy number of the transgene as compared to the copy number of the transgene in a second set of cells following selection of a second population of host cells grown in the presence of a neomycin phosphotransferase substrate, wherein the second population of host cells is transfected or transformed with a nucleic acid sequence comprising a nucleotide sequence encoding wild-type NPT protein and the transgene; and/or
(b) the selected cells achieve a 10 to 1000 fold higher level of expression of the transgene as compared to the level of expression of the transgene by a second set of cells following selection of a second population of host cells grown in the presence of a neomycin phosphotransferase substrate, wherein the second population of host cells is transfected or transformed with a nucleic acid sequence comprising a nucleotide sequence encoding wild-type NPT protein and the transgene.

### Claim 22 (depends on 20, 21)

The method of claim 20 or 21, wherein the host cells are bacterial cells, yeast cells, mammalian cells, plant cells; optionally wherein the mammalian cells are human cells.

### Claim 23 (depends on 20, 21)

The method of claim 20, 21, or 22, wherein the nucleic acid sequence is stably integrated into the genome of the selected cells.

### Claim 24 (depends on 20, 21, 22, 23)

The method of any one of claims 20 to 23, wherein the selected cells have a high copy number of the transgene.

### Claim 25 (depends on 20, 21, 22, 23, 24)

The method of any one of claims 20 to 24, wherein the selected cells have high level of expression of the transgene.

### Claim 26 (depends on 20, 21, 22, 23, 24, 25)

The method of any one of claims 20 to 25, wherein the selected cells have integrated 5 to 100 copies of the transgene into their genomic DNA.

### Claim 27 (depends on 20, 21, 22, 23, 24, 25)

The method of any one of claims 20 to 25, wherein the selected cells have integrated 1 to 5 copies of the transgene into their genomic DNA.

### Claim 28 (depends on 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 20 to 27, wherein the transgene comprises a viral gene or growth factor gene, or the transgene encodes a protein or non-coding RNA; wherein optionally, the non-coding RNA is selected from the group consisting of antisense RNA, miRNA, shRNA, long non-coding RNA, catalytic RNA, ribosomal RNA, tRNA or a guide RNA for a CRISPR nuclease; and wherein optionally, the protein is a therapeutic protein or antigen.

### Claim 29 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 20 to 28, wherein the neomycin phosphotransferase substrate is neomycin, kanamycin or G418.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of using a plasmid or transposon comprising a nucleic acid sequence encoding a non-naturally occurring NPT of any one of claims 1 to 10 as a selectable marker, the method comprising:
(a) introducing into a host cell the plasmid or transposon comprising the nucleic acid sequence encoding the non-naturally occurring NPT; and
(b) growing the cell in the presence of a neomycin phosphotransferase substrate.

### Claim 31 (depends on 30)

The method of claim 30, wherein the host cell is a bacterium, yeast cell, mammalian cell, plant cell; optionally wherein the mammalian cell is a human cell.

### Claim 32 (depends on 30, 31)

The method of claim 30 or 31, wherein the plasmid or transposon further comprises a second nucleotide sequence encoding a protein or a non-coding RNA; wherein optionally, the protein is a viral protein or a therapeutic protein; and wherein optionally, the non-coding RNA is shRNA, miRNA, antisense RNA, guide RNA for Crispr nucleases, catalytic RNA, ribosomal RNA, or tRNA.

### Claim 33 (depends on 30, 31, 32)

The method of any one of claims 30 to 32, wherein the neomycin phosphotransferase substrate is neomycin, kanamycin or G418.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of making host cells comprising a second nucleotide sequence comprising:
(a) introducing into a population of host cells a first nucleic acid sequence comprising (i) a first nucleotide sequence encoding the non-naturally occurring NPT of any one of claims 1 to 10, and (ii) a second nucleotide sequence comprising a transgene encoding a second protein or a non-coding RNA; wherein optionally, the second protein is a therapeutic protein or an antigen, or optionally the non-coding region is shRNA, miRNA, antisense RNA, guide RNA for Crispr nucleases, catalytic RNA, ribosomal RNA or tRNA;
(b) growing the population of host cells in the presence of a neomycin phosphotransferase substrate to produce colonies; and
(c) selecting a colony of cells that grows in the presence of the neomycin phosphotransferase substrate.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of making host cells comprising a second nucleotide sequence comprising:
(a) co-introducing into a population of host cells (i) a first nucleic acid sequence comprising a first nucleotide sequence encoding the non-naturally occurring NPT of any one of claims 1 to 10, and (ii) a second nucleic acid sequence comprising a transgene encoding a second protein or a non-coding RNA; wherein optionally, the second protein is a therapeutic protein or an antigen, or optionally the non-coding region is shRNA, miRNA, antisense RNA, guide RNA for Crispr nucleases, catalytic RNA, ribosomal RNA or tRNA;
(b) growing the population of host cells in the presence of a neomycin phosphotransferase substrate to produce colonies; and
(c) selecting a colony of cells that grows in the presence of the neomycin phosphotransferase substrate.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of making host cells comprising a second nucleotide sequence comprising:
(a) growing a population of hosts cells in the presence of a neomycin phosphotransferase substrate to produce colonies, wherein the population of host cells comprises (i) a first nucleic acid sequence comprising a first nucleotide sequence encoding the non-naturally occurring NPT of any one of claims 1 to 10, and (ii) a second nucleic acid sequence comprising a transgene encoding a second protein or a non-coding RNA; wherein optionally, the second protein is a therapeutic protein or an antigen, or optionally the non-coding region is shRNA, miRNA, antisense RNA, guide RNA for Crispr nucleases, catalytic RNA, ribosomal RNA or tRNA; and
(b) selecting a colony of cells that grows in the presence of the neomycin phosphotransferase substrate.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of making host cells comprising a second nucleotide sequence comprising:
(a) growing a population of hosts cells in the presence of a neomycin phosphotransferase substrate to produce colonies, wherein the population of host cells comprises (i) a first nucleic acid sequence comprising a first nucleotide sequence encoding the non-naturally occurring NPT of any one claims 1 to 10, and (ii) a second nucleic acid sequence comprising a transgene encoding a second protein or a non-coding RNA; wherein optionally, the second protein is a therapeutic protein or an antigen, or optionally the non-coding region is shRNA, miRNA, antisense RNA, guide RNA for Crispr nucleases, catalytic RNA, ribosomal RNA or tRNA; and
(b) selecting a colony of cells that grows in the presence of the neomycin phosphotransferase substrate.

### Claim 38 (depends on 34, 35, 36, 37)

The method of any one of claims 34 to 37, wherein the host cells are mammalian cells; optionally wherein the mammalian cells are human cells.

### Claim 39 (depends on 38)

The method of claim 38, wherein the mammalian cells are HEK293 cells, CHO cells, PER.C6 cells, murine NS0 cells, fibrosarcoma HT-1080 cells, murine Sp2/0 cells, BHK cells, or murine C127 cells.

### Claim 40 (depends on 34, 35, 36, 37, 38, 39)

The method of any one of claims 34 to 39, which further comprises culturing the selected colony of cells.

### Claim 41 (depends on 34, 35, 36, 37, 38, 39)

The method of any one of claims 34 to 39, wherein the neomycin phosphotransferase substrate is neomycin, kanamycin, or G418.

### Claim 42 (depends on 34, 35, 36, 37, 38, 39, 40, 41)

Host cells produced by the method of any one of claims 34 to 41.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method for manufacturing a stable cell line expressing a therapeutic protein or enzyme comprising:
(a) introducing one or more nucleic acid sequences into a population of host cells, wherein the one or more nucleic acid sequences comprise: (i) a first nucleic acid sequence encoding the non-naturally occurring neomycin phosphotransferase (NPT) of any one of claims 1 to 10; and (ii) a second nucleic acid sequence encoding the therapeutic protein or enzyme;
(b) selecting a cell from the population of cells of step (a) that grows in the presence of G418; and
(c) culturing the selected cell to produce a stable cell line expressing the therapeutic protein or enzyme.

### Claim 44 (depends on 43)

The method of claim 43, wherein the stable cell line expresses the therapeutic protein or enzyme, optionally wherein the therapeutic protein is an antibody or antibody fragment.

### Claim 45 (depends on 43, 44)

A stable cell line produced by the method of claim 43 or 44.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of making a virus producer cell line comprising:
(a) introducing one or more nucleic acid sequences into a population of host cells, wherein the one or more nucleic acid sequences comprise: (i) a first nucleic acid sequence encoding the non-naturally occurring neomycin phosphotransferase (NPT) of any one of claims 1 to 10; and (ii) a second nucleic acid sequence encoding one or more viral proteins, wherein the one or more viral proteins include a capsid protein, an envelope protein, a viral protein necessary for replication, or a combination thereof;
(b) selecting a cell from the population of cells that grows in the presence in of a neomycin phosphotransferase substrate; and
(c) propagating the selected cell to produce a virus producer cell line.

### Claim 47 (depends on 46)

The method of claim 46, wherein the one or more viral proteins include an AAV capsid protein; an AAV capsid protein and AAV rep protein; an envelope protein; adenovirus E1 region proteins required for adenovirus replication; a retroviral envelope protein; a retroviral gag protein; a retroviral reverse transcriptase; or a retroviral envelope protein, gag protein and reverse transcriptase.

### Claim 48 (depends on 46, 47)

A virus producer cell line made by the method of claim 46 or 47.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A virus producer cell line comprising one or more nucleic acid sequences, wherein the one or more nucleic acid sequences comprise:
(a) a first nucleic acid sequence encoding the non-naturally occurring neomycin phosphotransferase (NPT) of any one of claims 1 to 10; and
(b) a second nucleic acid sequence encoding one or more viral proteins, wherein the one or more viral proteins include a capsid protein, an envelope protein, a viral protein necessary for replication, or a combination thereof.

### Claim 50 (depends on 49)

The virus producer cell line of claim 49, wherein the one or more viral proteins includes an AAV capsid protein; an AAV capsid protein and AAV rep protein; an envelope protein;
adenovirus E1 region proteins required for adenovirus replication; a retroviral envelope protein;
a retroviral gag protein; a retroviral reverse transcriptase; or a retroviral envelope protein, gag protein and reverse transcriptase.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method for manufacturing a cell line expressing an antigen comprising:
(a) introducing one or more nucleic acid sequences into a population of host cells, wherein the one or more nucleic acid sequences comprise: (i) a first nucleic acid sequence encoding the non-naturally occurring neomycin phosphotransferase (NPT) of any one of claims 1 to 10; and (ii) a second nucleic acid sequence encoding an antigen; wherein optionally, the antigen is a viral antigen, a bacterial antigen, a fungal antigen, or a cancer antigen;
(b) selecting a cell from the population of cells of step (a) that grows in the presence of G418; and
(c) culturing the selected cell to produce a cell line expressing the antigen.

### Claim 52 (depends on 51)

An antigen producing cell line made by the method of claim 51.

### Claim 53 (depends on 43, 44, 46, 47, 51)

The method of claim 43, 44, 46, 47 or 51, wherein the cell line is a mammalian cell line; optionally wherein the mammalian cell line is a human cell line.

### Claim 54 (depends on 43, 44, 46, 47)

The method of claim 43, 44, 46, 47, or 51, wherein the cell line is a CHO, PER.C6, murine NS0, HEK293, fibrosarcoma HT-1080, murine Sp2/0, BHK, or murine C127 cell line.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

An antigen producing cell line comprising one or more nucleic acid sequences, wherein the one or more nucleic acid sequences comprise:
(a) a first nucleic acid sequence encoding the non-naturally occurring neomycin phosphotransferase (NPT) of any one of claims 1 to 10; and
(b) a second nucleic acid sequence encoding one or more antigens; wherein optionally, the one or more antigens is a viral antigen, a bacterial antigen, a fungal antigen or a cancer antigen.

### Claim 56 (depends on 45, 48, 49, 50, 52, 55)

The cell line of claim 45, 48, 49, 50, 52 or 55, wherein the cell line is a mammalian cell line; optionally wherein the mammalian cell line is a human cell line.

### Claim 57 (depends on 45, 48, 49, 50, 52)

The cell line of claim 45, 48, 49, 50, 52, or 55, wherein the cell line is a CHO, PER.C6, murine NS0, HEK293, fibrosarcoma HT-1080, murine Sp2/0, BHK, or murine C127 cell line.

### Claim 58

A selectable marker means for conferring resistance to kanamycin when introduced into a bacterial cell, and to G418 when introduced into a mammalian cell; wherein optionally, the selectable marker means comprises a nucleic acid sequence of SEQ ID NO:20; a nucleic acid sequence of SEQ ID NO:32; a nucleic acid sequence of SEQ ID NO:33; a nucleic acid sequence of SEQ ID NO:34; a nucleic acid sequence of SEQ ID NO:36; or a nucleic acid sequence of SEQ ID NO:37.

### Claim 59

A method for manufacturing a producer cell line comprising:
(a) transforming a bacterial or mammalian cell with an expression vector comprising a nucleic acid sequence encoding one or more viral proteins and a means for growing in the presence of kanamycin if the transformed cell is a bacterial cell and for growing in the presence of G418 if the transformed cell is a mammalian cell to make a transformed cell; and
(b) culturing the transformed cell in the presence of kanamycin or G418 to obtain a producer cell line, wherein the producer cell line expresses one or more viral proteins from AAV, adenovirus, retrovirus, lentivirus, herpes simplex virus, vaccinia virus or baculovirus.

### Claim 60

A method for selecting a cell with stable chromosomal integration of an exogenous nucleic acid sequence comprising:
(a) transforming a population of eukaryotic cells with an exogenous nucleic acid sequence comprising a means for growing in the presence of G418;
(b) culturing the population of transformed cells in the presence of G418 to produce colonies of transformed cells capable of growing in the presence of G418; and
(c) selecting a cell from a colony produced in step (b) to obtain a cell with a stable chromosomal integration of the exogenous nucleic acid; wherein optionally, the exogenous nucleic acid sequence further comprises a transgene, and the selected cell expresses the transgene; or the exogenous nucleic acid sequence disrupts expression of a gene endogenous to the selected cell.

### Claim 61

A method for selecting a mammalian cell with a stable episome comprising:
(a) transforming a population of mammalian cells with a plasmid comprising a means for growing in the presence of G418;
(b) culturing the population of transformed cells in the presence of G418 to produce colonies of transformed cells capable of growing in the presence of G418; and
(c) selecting a cell from a colony produced in step (b) to obtain a cell with a stable episome comprising the plasmid; wherein optionally, the plasmid further comprises an EBNA1 OriP nucleic acid sequence and the selected cell expresses EBNA1.

### Claim 62

A method for selecting a mammalian cell transiently expressing a transgene comprising:
(a) introducing into a population of mammalian cells a nucleic acid encoding a transgene and a means for growing in the presence of G418;
(b) culturing the population of mammalian cells in the presence of G418 for 48-72 hours; and
(c) selecting a mammalian cell from the cultured population of mammalian cells that grows in the presence of G418, wherein the selected mammalian cell transiently expresses the transgene; wherein optionally, the transgene comprises nucleic acid sequences encoding a Crispr endonuclease or a Crispr guide RNA.

### Claim 63 (depends on 59, 60, 61, 62)

The method of claim 59 to 62, wherein the means is nucleotide sequence encoding a non-naturally occurring neomycin phosphotransferase comprising the amino acid sequence selected from the group of SEQ ID NO: 38, 39, 40, 41, 42 and 43.
